Research summary
Research HubIpamorelin
Clinical — 10 studies
Ipamorelin is a selective growth hormone secretagogue studied for stimulating GH release with minimal effect on other pituitary hormones.
Being studied for
- Selective GH secretion
- Growth hormone pulse research
Published Research
Evidence profile
Human Phase 2 evidence
10 cited publications · 2 primary trials
Findings below belong to the studies that reported them. They describe the material and conditions those authors used, not this product, and not an outcome to expect.
Supporting evidence
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients
Beck DE et al. · International journal of colorectal disease · 2014
The study reportedIpamorelin 0.03-mg/kg twice daily for up to 7 days was well tolerated. There were no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses.
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers
Gobburu JV et al. · Pharmaceutical research · 1999
The study reportedThe proposed PK/PD model provides a useful characterization of ipamorelin disposition and GH responses across a range of doses.
Additional indexed literature (8)
- Preclinical · Mechanistic studyThe growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism
Lu Z et al. · Physiology & behavior · 2024 · PMID 39043357
- Preclinical · Mechanistic studyThe influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus
Gouda M et al. · Animal reproduction science · 2024 · PMID 38996787
- Preclinical · Mechanistic studyAttenuation of Visceral and Somatic Nociception by Ghrelin Mimetics
N Mohammadi E et al. · Journal of experimental pharmacology · 2020 · PMID 32801950
- Preclinical · Mechanistic studyGlycine-modified growth hormone secretagogues identified in seized doping material
Gajda PM et al. · Drug testing and analysis · 2019 · PMID 30136411
- Preclinical · Mechanistic studyA stable meta-carborane enables the generation of boron-rich peptide agonists targeting the ghrelin receptor
Worm DJ et al. · Journal of peptide science : an official publication of the European Peptide Society · 2018 · PMID 30168238
- Preclinical · Mechanistic studyStructure-activity relationship for peptídic growth hormone secretagogues
Ferro P et al. · Drug testing and analysis · 2017 · PMID 26811125
- Preclinical · Mechanistic studyDetermination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin
Semenistaya E et al. · Drug testing and analysis · 2015 · PMID 25869809
- Preclinical · Mechanistic studyEfficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus
Greenwood-Van Meerveld B et al. · Journal of experimental pharmacology · 2012 · PMID 27186127
Published studies summarised here concern the specific investigational or pharmaceutical materials and study conditions described by their authors. Their findings are not performance claims for Cobalt Peptides material. Citations verified against PubMed on 2026-08-09.
Notice
All information on this page is provided strictly for laboratory research and educational purposes only.